BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Levitsky J, Formica RN, Bloom RD, Charlton M, Curry M, Friedewald J, Friedman J, Goldberg D, Hall S, Ison M, Kaiser T, Klassen D, Klintmalm G, Kobashigawa J, Liapakis A, O'Conner K, Reese P, Stewart D, Terrault N, Theodoropoulos N, Trotter J, Verna E, Volk M. The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation. Am J Transplant. 2017;17:2790-2802. [PMID: 28556422 DOI: 10.1111/ajt.14381] [Cited by in Crossref: 202] [Cited by in F6Publishing: 175] [Article Influence: 40.4] [Reference Citation Analysis]
Number Citing Articles
1 Spearman CW, Dusheiko GM, Hellard M, Sonderup M. Hepatitis C. Lancet. 2019;394:1451-1466. [PMID: 31 DOI: 10.1016/s0140-6736(19)32320-7] [Cited by in Crossref: 108] [Cited by in F6Publishing: 56] [Article Influence: 2.3] [Reference Citation Analysis]
2 Chang SH, Merzkani M, Lentine KL, Wang M, Axelrod DA, Anwar S, Schnitzler MA, Wellen J, Chapman WC, Alhamad T. Trends in Discard of Kidneys from Hepatitis C Viremic Donors in the United States. Clin J Am Soc Nephrol 2021;16:251-61. [PMID: 33451990 DOI: 10.2215/CJN.10960720] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
3 Sawinski D, Forde KA, Wyatt CM. New Treatment Options for Hepatitis C Virus Infection in End-Stage Kidney Disease: To Treat or Not to Treat. American Journal of Kidney Diseases 2018;72:7-9. [DOI: 10.1053/j.ajkd.2018.01.049] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Moayedi Y, Gulamhusein AF, Ross HJ, Teuteberg JJ, Khush KK. Accepting hepatitis C virus-infected donor hearts for transplantation: Multistep consent, unrealized opportunity, and the Stanford experience. Clin Transplant 2018;32:e13308. [DOI: 10.1111/ctr.13308] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
5 Franco A, Moreso F, Sancho A, Esforzado N, Paul J, Llorente S, Crespo M, Guirado L, Melilli E, Roncero FG. Protocol for Optimizing the Use of Kidneys From Donors With Seropositivity for Hepatitis C Virus in Seronegative Recipients. Transplant Proc 2021;53:2655-8. [PMID: 34657711 DOI: 10.1016/j.transproceed.2021.09.013] [Reference Citation Analysis]
6 Alghamdi W, Lotfy K, Weernink C, Alsolami E, Jevnikar A, Luke P, Skaro A, Qumosani K, Brahmania M, Marotta P, Hosseini-moghaddam SM, Teriaky A. Hepatitis C positive organ transplantation to negative recipients at a multiorgan Canadian transplant centre: ready for prime time. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02107-1] [Reference Citation Analysis]
7 Kilic A, Hickey G, Mathier M, Sultan I, Gleason TG, Horn E, Keebler ME. Outcomes of Adult Heart Transplantation Using Hepatitis C-Positive Donors. J Am Heart Assoc 2020;9:e014495. [PMID: 31910781 DOI: 10.1161/JAHA.119.014495] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
8 Van Pilsum Rasmussen SE, Seaman S, Brown D, Desai N, Sulkowski M, Segev DL, Durand CM, Sugarman J. Patient's Perspectives of Experimental HCV-Positive to HCV-Negative Renal Transplantation: Report from a Single Site. AJOB Empir Bioeth 2020;11:40-52. [PMID: 31618112 DOI: 10.1080/23294515.2019.1670277] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Sawinski D, Forde KA, Lo Re V 3rd, Goldberg DS, Cohen JB, Locke JE, Bloom RD, Brensinger C, Weldon J, Shults J, Reese PP. Mortality and Kidney Transplantation Outcomes Among Hepatitis C Virus-Seropositive Maintenance Dialysis Patients: A Retrospective Cohort Study. Am J Kidney Dis 2019;73:815-26. [PMID: 30704882 DOI: 10.1053/j.ajkd.2018.11.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
10 Shudo Y, Cohen JE, Lingala B, He H, Zhu Y, Woo YJ. Impact of "increased-risk" donor hearts on transplant outcomes: A propensity-matched analysis. J Thorac Cardiovasc Surg 2019;157:603-10. [PMID: 30669225 DOI: 10.1016/j.jtcvs.2018.08.120] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
11 Prakash K, Aslam S. New updates in the world of hepatitis C virus infected organ transplantation. Curr Opin Organ Transplant 2020;25:364-70. [PMID: 32520787 DOI: 10.1097/MOT.0000000000000785] [Reference Citation Analysis]
12 Griffin JM, Chiu L, Axsom KM, Bijou R, Clerkin KJ, Colombo P, Cuomo MO, De Los Santos J, Fried JA, Goldsmith J, Habal M, Haythe J, Helmke S, Horn EM, Latif F, Hi Lee S, Lin EF, Naka Y, Raikhelkar J, Restaino S, Sayer GT, Takayama H, Takeda K, Teruya S, Topkara V, Tsai EJ, Uriel N, Yuzefpolskaya M, Farr MA, Maurer MS. United network for organ sharing outcomes after heart transplantation for al compared to ATTR cardiac amyloidosis. Clin Transplant 2020;34:e14028. [PMID: 32623785 DOI: 10.1111/ctr.14028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
13 Anesi JA, Goldberg DS. Maximizing Utilization of the Donor Pool by Appropriate Classification of Hepatitis C Antibody-Positive Donors. Am J Transplant 2017;17:2757-8. [DOI: 10.1111/ajt.14417] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
14 Fischer SA. Is This Organ Donor Safe?: Donor-Derived Infections in Solid Organ Transplantation. Infect Dis Clin North Am 2018;32:495-506. [PMID: 30146019 DOI: 10.1016/j.idc.2018.04.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
15 Durand CM, Chattergoon MA, Desai NM. Lessons from the real world: HCV-infected donor kidney transplantation as standard practice. Am J Transplant 2019;19:2969-70. [PMID: 31448520 DOI: 10.1111/ajt.15582] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
16 Dahlqvist G, Moreno C, Starkel P, Detry O, Coubeau L, Jochmans I. Innovations in liver transplantation in 2020, position of the Belgian Liver Intestine Advisory Committee (BeLIAC). Acta Gastroenterol Belg 2021;84:347-59. [PMID: 34217187 DOI: 10.51821/84.2.347] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Rivara MB, Formica RN, Mehrotra R. Advancing American Kidney Health-New Opportunities for Collaborative Care. Am J Med 2020;133:e335-7. [PMID: 32145208 DOI: 10.1016/j.amjmed.2020.01.036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
18 Wellington J, Ma A, Kottilil S, Ravichandran B, Husson J, Bruno D, Wilson E. Outcomes in Hepatitis C Positive Liver Transplantation: Timing of Direct-Acting Antiviral Treatment and Impact on Graft Fibrosis. Viruses 2021;13:1831. [PMID: 34578412 DOI: 10.3390/v13091831] [Reference Citation Analysis]
19 Feld JJ, Cypel M, Kumar D, Dahari H, Pinto Ribeiro RV, Marks N, Kamkar N, Bahinskaya I, Onofrio FQ, Zahoor MA, Cerrochi O, Tinckam K, Kim SJ, Schiff J, Reichman TW, McDonald M, Alba C, Waddell TK, Sapisochin G, Selzner M, Keshavjee S, Janssen HLA, Hansen BE, Singer LG, Humar A. Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study. Lancet Gastroenterol Hepatol. 2020;5:649-657. [PMID: 32389183 DOI: 10.1016/s2468-1253(20)30081-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
20 Terrault NA, Burton J, Ghobrial M, Verna E, Bayer J, Klein C, Victor D, Mohan S, Trotter J, Dodge J, Niemann CU, Rubin RA. Prospective Multicenter Study of Early Antiviral Therapy in Liver and Kidney Transplant Recipients of HCV-Viremic Donors. Hepatology 2021;73:2110-23. [PMID: 32926749 DOI: 10.1002/hep.31551] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
21 Ruck JM, Segev DL. Expanding deceased donor kidney transplantation: medical risk, infectious risk, hepatitis C virus, and HIV. Curr Opin Nephrol Hypertens 2018;27:445-53. [PMID: 30169460 DOI: 10.1097/MNH.0000000000000456] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
22 Anesi JA, Blumberg EA, Han JH, Lee DH, Clauss H, Climaco A, Hasz R, Molnar E, Alimenti D, West S, Bilker WB, Tolomeo P, Lautenbach E; CDC Prevention Epicenters Program. Risk factors for multidrug-resistant organisms among deceased organ donors. Am J Transplant 2019;19:2468-78. [PMID: 31162785 DOI: 10.1111/ajt.15488] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
23 Cohen E, Liapakis A. Pharmacokinetics and important drug-drug interactions to remember when treating advanced chronic kidney disease patients with hepatitis C direct acting anti-viral therapy. Semin Dial 2019;32:141-51. [PMID: 30557903 DOI: 10.1111/sdi.12763] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
24 Stewart ZA, Shah SA, Rolls JA, Guarrera JV, Kandaswamy R, Axelrod DA. Best practice recommendations for the use of hepatitis C viremic donor organs for hepatitis C virus naïve recipients. Clin Transplant 2021;:e14381. [PMID: 34086371 DOI: 10.1111/ctr.14381] [Reference Citation Analysis]
25 Delman AM, Ammann AM, Shah SA. The current status of virus-positive liver transplantation. Curr Opin Organ Transplant 2021;26:160-7. [PMID: 33595981 DOI: 10.1097/MOT.0000000000000850] [Reference Citation Analysis]
26 Rao V. Commentary: Expanding the donor pool: One virus at a time. J Thorac Cardiovasc Surg 2020:S0022-5223(20)32719-7. [PMID: 33189345 DOI: 10.1016/j.jtcvs.2020.09.114] [Reference Citation Analysis]
27 Levitsky J, Formica RN. Response to: HCV viremic donors with hepatic bridging fibrosis: Are we ready to use their livers in the era of direct-acting antivirals? Am J Transplant 2017;17:2988-2988. [DOI: 10.1111/ajt.14478] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
28 Chan S, Isbel NM, Hawley CM, Campbell SB, Campbell KL, Morrison M, Francis RS, Playford EG, Johnson DW. Infectious Complications Following Kidney Transplantation-A Focus on Hepatitis C Infection, Cytomegalovirus Infection and Novel Developments in the Gut Microbiota. Medicina (Kaunas) 2019;55:E672. [PMID: 31590269 DOI: 10.3390/medicina55100672] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
29 Weinfurtner K, Reddy KR. Hepatitis C viraemic organs in solid organ transplantation. J Hepatol. 2021;74:716-733. [PMID: 33212088 DOI: 10.1016/j.jhep.2020.11.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Da BL, Ezaz G, Kushner T, Crismale J, Kakked G, Gurakar A, Dieterich D, Schiano TD, Saberi B. Donor Characteristics and Regional Differences in the Utilization of HCV-Positive Donors in Liver Transplantation. JAMA Netw Open 2020;3:e2027551. [PMID: 33275155 DOI: 10.1001/jamanetworkopen.2020.27551] [Reference Citation Analysis]
31 Tasdogan BE, Akosman S, Gurakar M, Simsek C, Gurakar A. Update on Liver Transplantation: What is New Recently? Euroasian J Hepatogastroenterol 2019;9:34-9. [PMID: 31988865 DOI: 10.5005/jp-journals-10018-1293] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Kwong AJ, Wall A, Melcher M, Wang U, Ahmed A, Subramanian A, Kwo PY. Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors. Am J Transplant. 2019;19:1380-1387. [PMID: 30378723 DOI: 10.1111/ajt.15162] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 16.5] [Reference Citation Analysis]
33 Ohira M, Tanimine N, Kobayashi T, Ohdan H. Essential updates 2018/2019: Liver transplantation. Ann Gastroenterol Surg 2020;4:195-207. [PMID: 32490333 DOI: 10.1002/ags3.12321] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Logan C, Yumul I, Cepeda J, Pretorius V, Adler E, Aslam S, Martin NK. Cost-effectiveness of using hepatitis C viremic hearts for transplantation into HCV-negative recipients. Am J Transplant 2021;21:657-68. [PMID: 32777173 DOI: 10.1111/ajt.16245] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Fischer SA. Is This Organ Donor Safe?: Donor-Derived Infections in Solid Organ Transplantation. Surg Clin North Am 2019;99:117-28. [PMID: 30471737 DOI: 10.1016/j.suc.2018.09.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
36 Trapero-marugán M, Little EC, Berenguer M. Stretching the boundaries for liver transplant in the 21st century. The Lancet Gastroenterology & Hepatology 2018;3:803-11. [DOI: 10.1016/s2468-1253(18)30213-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
37 Somerville L, Doucette K. Hepatitis C: Current Controversies and Future Potential in Solid Organ Transplantation. Curr Infect Dis Rep 2018;20:18. [PMID: 29789956 DOI: 10.1007/s11908-018-0625-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
38 Saab S, Kardashian A, Saggi S, Choi G, Agopian V, Tong MJ. Use of hepatitis C-positive grafts in hepatitis C-negative liver transplant recipients is cost effective. Clin Transplant 2018;32:e13383. [PMID: 30129981 DOI: 10.1111/ctr.13383] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
39 Li SS, Osho A, Moonsamy P, D'Alessandro DA, Lewis GD, Villavicencio MA, Sundt TM 3rd, Funamoto M. Trends in the use of hepatitis C viremic donor hearts. J Thorac Cardiovasc Surg 2020:S0022-5223(20)32640-4. [PMID: 33487431 DOI: 10.1016/j.jtcvs.2020.09.044] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
40 Liapakis A, Formica RN, Levitsky J. Solid organ transplantation of viral hepatitis C positive donor organs into viral hepatitis C negative recipients. Curr Opin Organ Transplant 2018;23:257-63. [PMID: 29432255 DOI: 10.1097/MOT.0000000000000504] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 3.3] [Reference Citation Analysis]
41 Waller KMJ, De La Mata NL, Hedley JA, Rosales BM, O'Leary MJ, Cavazzoni E, Ramachandran V, Rawlinson WD, Kelly PJ, Wyburn KR, Webster AC. New blood-borne virus infections among organ transplant recipients: An Australian data-linked cohort study examining donor transmissions and other HIV, hepatitis C and hepatitis B notifications, 2000-2015. Transpl Infect Dis 2020;22:e13437. [PMID: 32767859 DOI: 10.1111/tid.13437] [Reference Citation Analysis]
42 Phillips KG, Ward AF, Ranganath NK, Malas J, Lonze BE, Moazami N, Angel LF, Kon ZN. Impact of the Opioid Epidemic on Lung Transplantation: Donor, Recipient, and Discard Characteristics. The Annals of Thoracic Surgery 2019;108:1464-70. [DOI: 10.1016/j.athoracsur.2019.05.065] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
43 Shelton BA, Sawinski D, Mehta S, Reed RD, Maclennan PA, Locke JE. Kidney transplantation and waitlist mortality rates among candidates registered as willing to accept a hepatitis C infected kidney. Transpl Infect Dis 2018;20:e12829. [DOI: 10.1111/tid.12829] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
44 Van Raemdonck D, Nevens F, Van Cleemput J, Vos R, Neyrinck A, Verleden GM. Fishing in the thoracic organ donor pool: What next if the catch of the day got infected with hepatitis C virus? J Thorac Cardiovasc Surg 2020;159:2121-5. [PMID: 31837768 DOI: 10.1016/j.jtcvs.2019.08.140] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
45 La Hoz RM, Sandıkçı B, Ariyamuthu VK, Tanriover B. Short-term outcomes of deceased donor renal transplants of HCV uninfected recipients from HCV seropositive nonviremic donors and viremic donors in the era of direct-acting antivirals. Am J Transplant 2019;19:3058-70. [PMID: 31207073 DOI: 10.1111/ajt.15496] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
46 Couri T, Aronsohn A. When Theory Becomes Reality: Navigating the Ethics of Transplanting Hepatitis C Virus-Positive Livers Into Negative Recipients. Clin Liver Dis (Hoboken) 2019;14:131-4. [PMID: 31709040 DOI: 10.1002/cld.849] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
47 Sise ME, Goldberg DS, Kort JJ, Schaubel DE, Alloway RR, Durand CM, Fontana RJ, Brown RS Jr, Friedewald JJ, Prenner S, Landis JR, Fernando M, Phillips CC, Woodle ES, Rike-Shields A, Sherman KE, Elias N, Williams WW, Gustafson JL, Desai NM, Barnaba B, Norman SP, Doshi M, Sultan ST, Aull MJ, Levitsky J, Belshe DS, Chung RT, Reese PP. Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection. J Am Soc Nephrol 2020;31:2678-87. [PMID: 32843477 DOI: 10.1681/ASN.2020050686] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 6.5] [Reference Citation Analysis]
48 Murag S, Dennis BB, Kim D, Ahmed A, Cholankeril G. Recent advances in liver transplantation with HCV seropositive donors. F1000Res 2019;8:F1000 Faculty Rev-2151. [PMID: 31942236 DOI: 10.12688/f1000research.20387.1] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
49 Esforzado N, Morales JM. Hepatitis C and kidney transplant: The eradication time of the virus has arrived. Nefrologia (Engl Ed) 2019;39:458-72. [PMID: 30905391 DOI: 10.1016/j.nefro.2019.01.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
50 Liyanage L, Muzaale AD, Henderson ML, Durand CM. Living kidney donation in individuals with hepatitis C and HIV infection: rationale and emerging evidence. Curr Transplant Rep 2019;6:167-76. [PMID: 32855901 DOI: 10.1007/s40472-019-00242-5] [Reference Citation Analysis]
51 Villegas-galaviz J, Anderson E, Guglin M. Clinical outcomes of heart transplantation using hepatitis c-viremic donors: a systematic review with meta-analysis. The Journal of Heart and Lung Transplantation 2022. [DOI: 10.1016/j.healun.2022.01.010] [Reference Citation Analysis]
52 Verna EC, Tsapepas D, Emond JC, Brown RS, Mohan S. Utilization of Hepatitis C Virus (HCV)‐Viremic Organs for HCV Negative Recipients: Is Practice Speeding Past the Evidence? Hepatology 2020;71:4-7. [DOI: 10.1002/hep.30933] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
53 Martini S, David E, Tandoi F, Dell Olio D, Salizzoni M, Saracco G, Romagnoli R. HCV viremic donors with hepatic bridging fibrosis: Are we ready to use their livers in the era of direct-acting antivirals? Am J Transplant 2017;17:2986-7. [DOI: 10.1111/ajt.14447] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
54 Goldberg DS, Levitsky J. Transplanting livers from HCV-infected donors into HCV-negative recipients: Promise but mind the pitfalls. Am J Transplant 2019;19:1264-5. [PMID: 30480869 DOI: 10.1111/ajt.15193] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Bethea E, Arvind A, Gustafson J, Andersson K, Pratt D, Bhan I, Thiim M, Corey K, Bloom P, Markmann J, Yeh H, Elias N, Kimura S, Dageforde LA, Cuenca A, Kawai T, Safa K, Williams W, Gilligan H, Sise M, Fishman J, Kotton C, Kim A, Rogers CC, Shao S, Cote M, Irwin L, Myoung P, Chung RT. Immediate administration of antiviral therapy after transplantation of hepatitis C-infected livers into uninfected recipients: Implications for therapeutic planning. Am J Transplant. 2020;20:1619-1628. [PMID: 31887236 DOI: 10.1111/ajt.15768] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
56 Frager SZ, Dhand A, Gass A, Levine A, Spielvogel D, Nog R, Wolf DC, Bodin RI. Heart Transplantation for Hepatitis C Virus Non-Viremic Recipients From Hepatitis C Virus Viremic Donors. Cardiol Rev 2019;27:179-81. [PMID: 31180937 DOI: 10.1097/CRD.0000000000000255] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
57 Bethea ED, Gaj K, Gustafson JL, Axtell A, Lebeis T, Schoenike M, Turvey K, Coglianese E, Thomas S, Newton-Cheh C, Ibrahim N, Carlson W, Ho JE, Shah R, Nayor M, Gift T, Shao S, Dugal A, Markmann J, Elias N, Yeh H, Andersson K, Pratt D, Bhan I, Safa K, Fishman J, Kotton C, Myoung P, Villavicencio MA, D'Alessandro D, Chung RT, Lewis GD. Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study. Lancet Gastroenterol Hepatol. 2019;4:771-780. [PMID: 31353243 DOI: 10.1016/s2468-1253(19)30240-7] [Cited by in Crossref: 34] [Cited by in F6Publishing: 9] [Article Influence: 11.3] [Reference Citation Analysis]
58 Aslam S, Yumul I, Mariski M, Pretorius V, Adler E. Outcomes of heart transplantation from hepatitis C virus–positive donors. The Journal of Heart and Lung Transplantation 2019;38:1259-67. [DOI: 10.1016/j.healun.2019.08.019] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
59 de Vera ME, Volk ML, Ncube Z, Blais S, Robinson M, Allen N, Evans R, Weissman J, Baron P, Kore A, Bratton C, Garnett G, Hoang T, Wai P, Villicana R. Transplantation of hepatitis C virus (HCV) antibody positive, nucleic acid test negative donor kidneys to HCV negative patients frequently results in seroconversion but not HCV viremia. Am J Transplant 2018;18:2451-6. [DOI: 10.1111/ajt.15031] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 9.0] [Reference Citation Analysis]
60 King KL, Husain SA, Mohan S. Trends in Transplantation Center Use of Kidneys From Deceased Donors With Positive Hepatitis C Virus Nucleic Acid Testing. Am J Kidney Dis 2020;76:743-6. [PMID: 32479923 DOI: 10.1053/j.ajkd.2020.04.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
61 Kappus MR, Wolfe CR, Muir AJ. Direct-Acting Antivirals and Organ Transplantation: Is There Anything We Can't Do? J Infect Dis. 2020;222:S794-S801. [PMID: 33245347 DOI: 10.1093/infdis/jiaa420] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
62 Vandendriessche K, Nevens F, Van Cleemput J, Van Raemdonck D, Rega F. Commentary: Hepatitis: A way to make organ donation go viral? J Thorac Cardiovasc Surg 2019;158:554-5. [PMID: 31196756 DOI: 10.1016/j.jtcvs.2019.02.141] [Reference Citation Analysis]
63 Chacon MM, Adams AJ, Kassel CA, Markin NW. High-Risk and Hepatitis C-Positive Organ Donors: Current Practice in Heart, Lung, and Liver Transplantation. J Cardiothorac Vasc Anesth 2020;34:2492-500. [PMID: 31954619 DOI: 10.1053/j.jvca.2019.12.012] [Reference Citation Analysis]
64 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int Suppl (2011) 2018;8:91-165. [PMID: 30675443 DOI: 10.1016/j.kisu.2018.06.001] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 15.3] [Reference Citation Analysis]
65 Buganza-torio E, Doucette KE. Management of Viral Hepatitis in Solid Organ Transplant Recipients. Infectious Disease Clinics of North America 2018;32:635-50. [DOI: 10.1016/j.idc.2018.04.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
66 Sibulesky L, Kling CE, Blosser C, Johnson CK, Limaye AP, Bakthavatsalam R, Leca N, Perkins JD. Are we underestimating the quality of aviremic hepatitis C-positive kidneys? Time to reconsider. Am J Transplant 2018;18:2465-72. [PMID: 29451354 DOI: 10.1111/ajt.14701] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
67 Doulamis IP, Tzani A, Moustakidis S, Kampaktsis PN, Briasoulis A. Effect of Hepatitis C donor status on heart transplantation outcomes in the United States. Clin Transplant 2021;35:e14220. [PMID: 33420730 DOI: 10.1111/ctr.14220] [Reference Citation Analysis]
68 Kukreja J, Chen J, Brzezinski M. Redefining marginality: donor lung criteria. Current Opinion in Organ Transplantation 2020;25:280-4. [DOI: 10.1097/mot.0000000000000764] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
69 Madan S, Patel SR, Rahgozar K, Saeed O, Murthy S, Vukelic S, Sims DB, Shin JJ, Goldstein DJ, Jorde UP. Utilization rates and clinical outcomes of hepatitis C positive donor hearts in the contemporary era. The Journal of Heart and Lung Transplantation 2019;38:907-17. [DOI: 10.1016/j.healun.2019.06.023] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
70 Calogero A, Sagnelli E, Creta M, Angeletti S, Peluso G, Incollingo P, Candida M, Minieri G, Carlomagno N, Dodaro CA, Ciccozzi M, Sagnelli C. Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients. Biomed Res Int. 2019;2019:4674560. [PMID: 31179323 DOI: 10.1155/2019/4674560] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
71 Cuvelier S, Van Caeseele P, Kadatz M, Peterson K, Sun S, Dodd N, Werestiuk K, Koulack J, Nickerson P, Ho J. Expanding the Deceased Donor Pool in Manitoba Using Hepatitis C-Viremic Donors: Program Report. Can J Kidney Health Dis 2021;8:20543581211033496. [PMID: 34367648 DOI: 10.1177/20543581211033496] [Reference Citation Analysis]
72 Nangia G, Borges K, Reddy KR. Use of HCV‐infected organs in solid organ transplantation: An ethical challenge but plausible option. J Viral Hepat 2019;26:1362-71. [DOI: 10.1111/jvh.13130] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
73 Anwar N, Kaiser TE, Bari K, Schoech M, Diwan TS, Cuffy MC, Silski L, Quillin RC, Safdar K, Shah SA. Use of Hepatitis C Nucleic Acid Test–Positive Liver Allografts in Hepatitis C Virus Seronegative Recipients. Liver Transpl 2020;26:673-80. [DOI: 10.1002/lt.25741] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
74 Salvadori M, Tsalouchos A. Hepatitis C and renal transplantation in era of new antiviral agents. World J Transplant 2018; 8(4): 84-96 [PMID: 30148074 DOI: 10.5500/wjt.v8.i4.84] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
75 Dao A, Cuffy M, Kaiser TE, Loethen A, Cafardi J, Luckett K, Rike AH, Cardi M, Alloway RR, Govil A, Diwan T, Sherman KE, Shah SA, Woodle ES. Use of HCV Ab+/NAT- donors in HCV naïve renal transplant recipients to expand the kidney donor pool. Clin Transplant 2019;33:e13598. [PMID: 31104346 DOI: 10.1111/ctr.13598] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
76 Nair SP, Marella HK, Maliakkal B, Snyder H, Handley C, Kothadia JP, Ali B, Satapathy SK, Molnar MZ, Clark I, Jain R, Helmick R, Eymard C, Eason JD. Transplantation of liver from hepatitis C-infected donors to hepatitis C RNA-negative recipients: Histological and virologic outcome. Clin Transplant 2021;35:e14281. [PMID: 33690929 DOI: 10.1111/ctr.14281] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Gupta G, Zhang Y, Carroll NV, Sterling RK. Cost-effectiveness of hepatitis C-positive donor kidney transplantation for hepatitis C-negative recipients with concomitant direct-acting antiviral therapy. Am J Transplant 2018;18:2496-505. [DOI: 10.1111/ajt.15054] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 7.8] [Reference Citation Analysis]
78 Delman AM, Turner KM, Safdar K, Anwar N, Silski LS, Lee TC, Luckett K, Cuffy MC, Quillin RC 3rd, Schoech M, Kaiser TE, Govil A, Bari K, Shah SA. Expanding the Donor Pool: First Use of Hepatitis B Virus Nat Positive Solid Organ Allografts Into Seronegative Recipients. Ann Surg 2021;274:556-64. [PMID: 34506310 DOI: 10.1097/SLA.0000000000005071] [Reference Citation Analysis]
79 Potluri VS, Goldberg DS, Mohan S, Bloom RD, Sawinski D, Abt PL, Blumberg EA, Parikh CR, Sharpe J, Reddy KR, Molnar MZ, Sise M, Reese PP. National Trends in Utilization and 1-Year Outcomes with Transplantation of HCV-Viremic Kidneys. J Am Soc Nephrol. 2019;30:1939-1951. [PMID: 31515244 DOI: 10.1681/asn.2019050462] [Cited by in Crossref: 36] [Cited by in F6Publishing: 16] [Article Influence: 12.0] [Reference Citation Analysis]
80 Farmakiotis D, Weiss Z, Brotherton AL, Morrissey P, Gohh R, Vieira K, Taylor LE, Garland JM. Successful Kidney Transplantation in a Recipient Coinfected with Hepatitis C Genotype 2 and HIV from a Donor Infected with Hepatitis C Genotype 1 in the Direct-Acting Antiviral Era. Case Reports Hepatol 2020;2020:7679147. [PMID: 32082657 DOI: 10.1155/2020/7679147] [Reference Citation Analysis]
81 Theodoropoulos N, Kroll‐desrosiers A, Ison MG. Utilization of deceased organ donors based on HIV, hepatitis B virus, and hepatitis C virus screening test results. Transpl Infect Dis 2020;22. [DOI: 10.1111/tid.13275] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
82 Bari K, Luckett K, Kaiser T, Diwan T, Cuffy M, Schoech MR, Safdar K, Blackard JT, Apewokin S, Paterno F, Sherman KE, Zucker SD, Anwar N, Shah SA. Hepatitis C transmission from seropositive, nonviremic donors to non-hepatitis C liver transplant recipients. Hepatology. 2018;67:1673-1682. [PMID: 29205441 DOI: 10.1002/hep.29704] [Cited by in Crossref: 67] [Cited by in F6Publishing: 60] [Article Influence: 16.8] [Reference Citation Analysis]
83 Sise ME, Strohbehn IA, Chute DF, Gustafson J, Van Deerlin VM, Smith JR, Gentile C, Wojciechowski D, Williams WW, Elias N, Chung RT. Preemptive Treatment With Elbasvir and Grazoprevir for Hepatitis C-Viremic Donor to Uninfected Recipient Kidney Transplantation. Kidney Int Rep 2020;5:459-67. [PMID: 32280841 DOI: 10.1016/j.ekir.2020.01.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
84 Wigneswaran J, Van Wyck D, Pegues D, Gholam P, Nissenson AR. Hepatitis C virus infection in patients with end-stage renal disease: Hepatitis C in renal patients. Hemodialysis International 2018;22:297-307. [DOI: 10.1111/hdi.12672] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
85 Martin EF. Paradigm Shift in Utilization of Livers from Hepatitis C-Viremic Donors into Hepatitis C Virus-Negative Patients. Clin Liver Dis 2021;25:195-207. [PMID: 33978579 DOI: 10.1016/j.cld.2020.08.009] [Reference Citation Analysis]
86 Couri T, Aronsohn A. You Can't Have One Without the Other: Innovation and Ethical Dilemmas in Gastroenterology and Hepatology. Clin Gastroenterol Hepatol 2021;19:2015-9. [PMID: 32445954 DOI: 10.1016/j.cgh.2020.05.024] [Reference Citation Analysis]
87 Patel SR, Madan S, Saeed O, Sims DB, Shin JJ, Nucci C, Borukhov E, Goldstein DY, Jakobleff W, Forest S, Vukelic S, Murthy S, Reinus J, Puius Y, Goldstein DJ, Jorde UP. Cardiac transplantation from non-viremic hepatitis C donors. The Journal of Heart and Lung Transplantation 2018;37:1254-60. [DOI: 10.1016/j.healun.2018.06.012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
88 Martin P. Inflexion of the curve: Hepatitis C's waning role in liver transplantation. Liver Transpl 2018;24:727-8. [PMID: 29878534 DOI: 10.1002/lt.25201] [Reference Citation Analysis]
89 Ghany MG, Morgan TR;  AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2020;71:686-721. [PMID: 31816111 DOI: 10.1002/hep.31060] [Cited by in Crossref: 145] [Cited by in F6Publishing: 133] [Article Influence: 72.5] [Reference Citation Analysis]
90 Cannon RM, Locke JE, Orandi BJ, Anderson DJ, Davis EG, Mackelaite L, Dave H, Eng M, Jones CM. Impact of Donor Hepatitis C Virus on Kidney Transplant Outcomes for Hepatitis C-positive Recipients in the Direct-acting Antiviral Era: Time to Revise the Kidney Donor Risk Index? Transplantation 2020;104:1215-28. [PMID: 31517783 DOI: 10.1097/TP.0000000000002949] [Cited by in Crossref: 9] [Article Influence: 4.5] [Reference Citation Analysis]
91 Sibulesky L, Limaye AP. Hepatitis C NAT status in the UNOS database. Am J Transplant 2019;19:1870-1870. [DOI: 10.1111/ajt.15303] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
92 Griffiths P, Haque T, Marshall A. Management of HCV peri-transplant recapitulates management of CMV. Rev Med Virol 2019;29:e2091. [PMID: 31709643 DOI: 10.1002/rmv.2091] [Reference Citation Analysis]
93 Schlendorf KH, Zalawadiya S, Shah AS, Wigger M, Chung CY, Smith S, Danter M, Choi CW, Keebler ME, Brinkley DM, Sacks SB, Ooi H, Perri R, Awad JA, Lewis S, Hayes R, O'Dell H, Darragh C, Carver A, Edmonds C, Ruzevich-Scholl S, Lindenfeld J. Early outcomes using hepatitis C-positive donors for cardiac transplantation in the era of effective direct-acting anti-viral therapies. J Heart Lung Transplant 2018;37:763-9. [PMID: 29530322 DOI: 10.1016/j.healun.2018.01.1293] [Cited by in Crossref: 113] [Cited by in F6Publishing: 91] [Article Influence: 28.3] [Reference Citation Analysis]
94 Gernhofer YK, Brambatti M, Greenberg BH, Adler E, Aslam S, Pretorius V. The impact of using hepatitis c virus nucleic acid test-positive donor hearts on heart transplant waitlist time and transplant rate. J Heart Lung Transplant 2019;38:1178-88. [PMID: 31492607 DOI: 10.1016/j.healun.2019.08.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
95 Danford CJ, Curry MP. Over 2 Decades of Transplanting Hepatitis C Virus-Positive Liver Allografts: Almost Full Circle With Encouraging Early Results. Liver Transpl 2020;26:626-7. [PMID: 32173967 DOI: 10.1002/lt.25754] [Reference Citation Analysis]
96 Kadatz M, Klarenbach S, Gill J, Gill JS. Cost-effectiveness of using kidneys from hepatitis C nucleic acid test-positive donors for transplantation in hepatitis C-negative recipients. Am J Transplant 2018;18:2457-64. [DOI: 10.1111/ajt.14929] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
97 Kling CE, Perkins JD, Biggins SW, Johnson CK, Limaye AP, Sibulesky L. Listing practices and graft utilization of hepatitis C-positive deceased donors in liver and kidney transplant. Surgery 2019;166:102-8. [PMID: 31072671 DOI: 10.1016/j.surg.2019.03.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
98 Prakash K, Wainana C, Trageser J, Hahn A, Lay C, Pretorius V, Adler E, Aslam S. Local and regional variability in utilization and allocation of hepatitis C virus-infected hearts for transplantation. Am J Transplant 2020;20:2867-75. [PMID: 32185860 DOI: 10.1111/ajt.15857] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
99 White SL, Rawlinson W, Boan P, Sheppeard V, Wong G, Waller K, Opdam H, Kaldor J, Fink M, Verran D, Webster A, Wyburn K, Grayson L, Glanville A, Cross N, Irish A, Coates T, Griffin A, Snell G, Alexander SI, Campbell S, Chadban S, Macdonald P, Manley P, Mehakovic E, Ramachandran V, Mitchell A, Ison M. Infectious Disease Transmission in Solid Organ Transplantation: Donor Evaluation, Recipient Risk, and Outcomes of Transmission. Transplant Direct 2019;5:e416. [PMID: 30656214 DOI: 10.1097/TXD.0000000000000852] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 4.8] [Reference Citation Analysis]
100 Kulkarni HS, Korenblat KM, Kreisel D. Expanding the donor pool for lung transplantation using HCV-positive donors. J Thorac Dis 2019;11:S1942-6. [PMID: 31632793 DOI: 10.21037/jtd.2019.08.27] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
101 Selzner N, Berenguer M. Should organs from hepatitis C-positive donors be used in hepatitis C-negative recipients for liver transplantation? Liver Transpl 2018;24:831-40. [DOI: 10.1002/lt.25072] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
102 Shike H, Kadry Z, Imamura-Kawasawa Y, Greene W, Riley T, Nathan HM, Hasz RD, Jain A. Hepatitis C virus (HCV) RNA level in plasma and kidney tissue in HCV antibody-positive donors: Quantitative comparison. Clin Transplant 2018;32:e13358. [PMID: 30044009 DOI: 10.1111/ctr.13358] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
103 Crismale JF, Khalid M, Bhansali A, De Boccardo G, Khaim R, Florman SS, Shapiro R, Schiano TD. Liver, simultaneous liver-kidney, and kidney transplantation from hepatitis C-positive donors in hepatitis C-negative recipients: A single-center study. Clin Transplant 2020;34:e13761. [PMID: 31808193 DOI: 10.1111/ctr.13761] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
104 Pérez IB, Duca A. Top Papers in Liver Transplantation 2017-2018. Transplant Proc 2021;53:620-3. [PMID: 32247594 DOI: 10.1016/j.transproceed.2020.01.085] [Reference Citation Analysis]
105 Fishman JA, Forns X. HCV-Positive Donor Organs in Solid Organ Transplantation: “Mind the Gap!”. Am J Transplant 2017;17:2755-6. [DOI: 10.1111/ajt.14396] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
106 Shetty A, Buch A, Saab S. Use of Hepatitis C-Positive Liver Grafts in Hepatitis C-Negative Recipients. Dig Dis Sci 2019;64:1110-8. [PMID: 30560331 DOI: 10.1007/s10620-018-5404-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
107 Solli P, Dolci G, Ranieri VM. The new frontier of hepatitis C virus (HCV)-mismatched heart and lung transplantation. Ann Transl Med 2019;7:S279. [PMID: 32015998 DOI: 10.21037/atm.2019.11.123] [Reference Citation Analysis]
108 Mitchell RA, Hussaini T, Yau AH, Krajden M, Wright AJ, Scudamore CH, Marquez Azalgara V, Erb SR, Yoshida EM. Transplantation of a Liver Allograft From a Hepatitis C Virus Seropositive Donor With Previous Sustained Virologic Response to an Uninfected Recipient Suffering Steroid Refractory Acute Graft Rejection With No Evidence of HCV Transmission. Transplant Direct 2018;4:e347. [PMID: 29707618 DOI: 10.1097/TXD.0000000000000763] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
109 Gill JS, Formica RN, Levitsky J. Transplantation of Kidneys from HCV Viremic Donors in the United States: A Missed Opportunity to Inform Clinical Decision Making and Health Policy. J Am Soc Nephrol 2019;30:1778-80. [PMID: 31570540 DOI: 10.1681/ASN.2019070726] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
110 Crismale JF, Ahmad J. Expanding the donor pool: Hepatitis C, hepatitis B and human immunodeficiency virus-positive donors in liver transplantation. World J Gastroenterol 2019; 25(47): 6799-6812 [PMID: 31885421 DOI: 10.3748/wjg.v25.i47.6799] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
111 McCauley M, Mussell A, Goldberg D, Sawinski D, Molina RN, Tomlin R, Doshi SD, Abt P, Bloom R, Blumberg E, Kulkarni S, Esnaola G, Shults J, Thiessen C, Reese PP. Race, Risk, and Willingness of End-Stage Renal Disease Patients Without Hepatitis C Virus to Accept an HCV-Infected Kidney Transplant. Transplantation 2018;102:e163-70. [PMID: 29346260 DOI: 10.1097/TP.0000000000002099] [Cited by in Crossref: 24] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
112 Cotter TG, Aronsohn A, Reddy KG, Charlton M. Liver Transplantation of HCV-viremic Donors Into HCV-negative Recipients in the United States: Increasing Frequency With Profound Geographic Variation. Transplantation 2021;105:1285-90. [DOI: 10.1097/tp.0000000000003382] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
113 Franco A, Moreso F, Merino E, Sancho A, Kanter J, Gimeno A, Balibrea N, Rodriguez M, Perez Contreras F. Renal transplantation from seropositive hepatitis C virus donors to seronegative recipients in Spain: a prospective study. Transpl Int 2019;32:710-6. [PMID: 30773693 DOI: 10.1111/tri.13410] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
114 Kwong AJ, Terrault NA. Use of hepatitis C viraemic organs in kidney transplantation: a need to hit the pause button? Nat Rev Gastroenterol Hepatol 2019;16:5-6. [PMID: 30333527 DOI: 10.1038/s41575-018-0071-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
115 Bohorquez H, Bugeaud E, Bzowej N, Scheuermann J, Hand J, Bruce D, Carmody I, Cohen A, Joshi S, Seal J, Sonnier D, Therapondos G, Girgrah N, Anders S, Loss GE. Liver Transplantation Using Hepatitis C Virus-Viremic Donors Into Hepatitis C Virus-Aviremic Recipients as Standard of Care. Liver Transpl. 2020;. [PMID: 33098277 DOI: 10.1002/lt.25925] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
116 Theodoropoulos N, Nowicki MJ, Chinchilla-reyes C, Dionne S, Jaramillo A, Mone T, Hasz R, Jendrisak MD, Ladner DP, Ison MG. Deceased organ donor screening for human immunodeficiency virus, hepatitis B virus and hepatitis C virus: Discordant serology and nucleic acid testing results. Transpl Infect Dis 2018;20:e12821. [DOI: 10.1111/tid.12821] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
117 Dejman A, Ladino MA, Roth D. Treatment and management options for the hepatitis C virus infected kidney transplant candidate. Hemodial Int 2018;22 Suppl 1:S36-44. [PMID: 29694726 DOI: 10.1111/hdi.12646] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
118 Sise ME, Strohbehn IA, Bethea E, Gustafson JL, Chung RT. Balancing the risk and rewards of utilizing organs from hepatitis C viremic donors. Curr Opin Organ Transplant 2019;24:351-7. [PMID: 31090648 DOI: 10.1097/MOT.0000000000000651] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
119 Ting PS, Hamilton JP, Gurakar A, Urrunaga NH, Ma M, Glorioso J, King E, Toman LP, Wesson R, Garonzik-Wang J, Ottmann S, Philosophe B, Sulkowski M, Cameron AM, Durand CM, Chen PH. Hepatitis C-positive donor liver transplantation for hepatitis C seronegative recipients. Transpl Infect Dis 2019;21:e13194. [PMID: 31609520 DOI: 10.1111/tid.13194] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
120 Diwan TS, Lee TC, Nagai S, Benedetti E, Posselt A, Bumgardner G, Noria S, Whitson BA, Ratner L, Mason D, Friedman J, Woodside KJ, Heimbach J. Obesity, transplantation, and bariatric surgery: An evolving solution for a growing epidemic.Am J Transplant. 2020;20:2143-2155. [PMID: 31965711 DOI: 10.1111/ajt.15784] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
121 Shaffer AA, Thomas AG, Bowring MG, Van Pilsum Rasmussen SE, Cash A, Kucirka LM, Alqahtani SA, Gurakar A, Sulkowski MS, Cameron AM, Segev DL, Durand CM. Changes in practice and perception of hepatitis C and liver transplantation: Results of a national survey. Transpl Infect Dis 2018;20:e12982. [PMID: 30144258 DOI: 10.1111/tid.12982] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
122 Verna EC, Goldberg DS. Hepatitis C viremic donors for hepatitis C nonviremic liver transplant recipients: Ready for prime time?: Verna and Goldberg. Liver Transpl 2018;24:12-4. [DOI: 10.1002/lt.24985] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
123 Burton JR Jr, Terrault NA, Goldberg DS, Bloom RD, Gilroy R, Heimbach JK, Brown RS Jr, Everson GT, Rubin E, Wiesner R, Pomfret EA. Liver and Kidney Recipient Selection of Hepatitis C Virus Viremic Donors: Meeting Consensus Report From the 2019 Controversies in Transplantation. Transplantation 2020;104:476-81. [PMID: 31634329 DOI: 10.1097/TP.0000000000003014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
124 Aguilar C, Husain S, Lortholary O. Recent advances in understanding and managing infectious diseases in solid organ transplant recipients. F1000Res 2018;7:F1000 Faculty Rev-661. [PMID: 29899970 DOI: 10.12688/f1000research.14262.1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
125 Alric L, Ollivier-Hourmand I, Bérard E, Hillaire S, Guillaume M, Vallet-Pichard A, Bernard-Chabert B, Loustaud-Ratti V, Bourlière M, de Ledinghen V, Fouchard-Hubert I, Canva V, Minello A, Nguyen-Khac E, Leroy V, Saadoun D, Trias D, Pol S, Kamar N. Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective. Kidney Int 2018;94:206-13. [PMID: 29735308 DOI: 10.1016/j.kint.2018.02.019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
126 Shah KS, Kittleson MM, Kobashigawa JA. Updates on Heart Transplantation. Curr Heart Fail Rep 2019;16:150-6. [DOI: 10.1007/s11897-019-00432-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
127 Gonzalez SA, Trotter JF. The rise of the opioid epidemic and hepatitis C-positive organs: A new era in liver transplantation: Gonzalez and Trotter. Hepatology 2018;67:1600-8. [DOI: 10.1002/hep.29572] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 11.0] [Reference Citation Analysis]
128 Ariyamuthu VK, Sandikci B, Abdulrahim N, Hwang C, Macconmara MP, Parasuraman R, Atis A, Tanriover B. Trends in utilization of deceased donor kidneys based on hepatitis C virus status and impact of public health service labeling on discard. Transpl Infect Dis 2019;22. [DOI: 10.1111/tid.13204] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
129 Çiftçibaşı Örmeci A, Yıldız Ç, Saberi B, Gürakar M, Şimşek C, Gürakar A. Usage of HCV viremic organs in liver transplantation to anti-HCV negative recipients: The current status and review of literature. Turk J Gastroenterol 2019;30:771-5. [PMID: 31530520 DOI: 10.5152/tjg.2019.18656] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
130 Moayedi Y, Ross HJ, Khush KK. Disclosure of infectious risk to heart transplant candidates: Shared decision-making is here to stay. J Heart Lung Transplant 2018;37:564-7. [PMID: 29395752 DOI: 10.1016/j.healun.2017.12.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
131 Harano T, Haidar G, Schaheen L, Morrell MR, Pilewski JM, D'Cunha J. Successful lung transplantation from a hepatitis C RNA-positive donor to a hepatitis C treatment-experienced recipient with cystic fibrosis. J Thorac Cardiovasc Surg 2019;158:e155-7. [PMID: 31229293 DOI: 10.1016/j.jtcvs.2019.05.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
132 Ising MS, Gallo M, Whited WM, Slaughter MS, Trivedi JR. Changing demographics of heart donors: The impact of donor drug intoxication on posttransplant survival. Am J Transplant 2018;18:1790-8. [PMID: 29513379 DOI: 10.1111/ajt.14726] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
133 Chan EG, Chan PG, Sanchez PG. Expanding the pool: the use of hepatitis C RNA positive organs in lung transplantation. J Thorac Dis 2019;11:S1888-90. [PMID: 31632776 DOI: 10.21037/jtd.2019.08.76] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
134 Roth D, Ladino M. Transplantation of Kidneys from HCV-Positive Donors: How to Best Use a Scarce Resource. J Am Soc Nephrol 2017;28:3139-41. [PMID: 28874402 DOI: 10.1681/ASN.2017060673] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
135 Trotter PB, Summers DM, Ushiro-Lumb I, Robb M, Bradley JA, Powell J, Watson CJE, Neuberger J. Use of Organs From Hepatitis C Virus-Positive Donors for Uninfected Recipients: A Potential Cost-Effective Approach to Save Lives? Transplantation 2018;102:664-72. [PMID: 29166338 DOI: 10.1097/TP.0000000000002033] [Cited by in Crossref: 32] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
136 Verna EC, Schluger A, Brown RS Jr. Opioid epidemic and liver disease. JHEP Rep 2019;1:240-55. [PMID: 32039374 DOI: 10.1016/j.jhepr.2019.06.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
137 Holscher CM, Durand CM, Desai NM. Expanding the Use of Organs From Hepatitis C-Viremic Donors: The Evidence Continues to Build. Transplantation 2018;102:546-7. [PMID: 29176392 DOI: 10.1097/TP.0000000000002032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
138 Badawy A, Kaido T, Uemoto S. Current Status of Liver Transplantation Using Marginal Grafts. Journal of Investigative Surgery 2020;33:553-64. [DOI: 10.1080/08941939.2018.1517197] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
139 Te H, Doucette K. Viral hepatitis: Guidelines by the American Society of Transplantation Infectious Disease Community of Practice. Clin Transplant 2019;33. [DOI: 10.1111/ctr.13514] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
140 Len O, Los-Arcos I, Aguado JM, Blanes M, Bodro M, Carratalà J, Cordero E, Fariñas MC, Fernández-Ruiz M, Fortún J, Gavaldà J, López-Medrano F, López-Vélez R, Lumbreras C, Mahillo B, Marcos MÁ, Martin-Dávila P, Montejo JM, Moreno A, Muñoz P, Norman F, Pérez-Sáenz JL, Pumarola T, Sabé N, San-Juan R, Vidal E, Domínguez-Gil B; Grupo de Estudio de la Infección en el Trasplante (GESITRA) of the Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC) and the Organización Nacional de Trasplantes (ONT). Selection criteria of solid organ donors in relation to infectious diseases: A Spanish consensus. Transplant Rev (Orlando) 2020;34:100528. [PMID: 32001103 DOI: 10.1016/j.trre.2020.100528] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
141 Feld JJ, Gehring AJ. Host-pathogen interactions in chronic HBV infection and transplantation of HCV-positive organs. Nat Rev Gastroenterol Hepatol 2019;16:77-8. [PMID: 30617296 DOI: 10.1038/s41575-018-0101-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
142 Stewart ZA, Stern J, Ali NM, Kalia HS, Khalil K, Jonchhe S, Weldon EP, Dieter RA, Lewis TC, Funches N, Crosby S, Seow M, Berger JC, Dagher NN, Gelb BE, Watkins AC, Moazami N, Smith DE, Kon ZN, Chang SH, Reyentovich A, Angel LF, Montgomery RA, Lonze BE. Clinical and Financial Implications of 2 Treatment Strategies for Donor-derived Hepatitis C Infections. Transplant Direct 2021;7:e762. [PMID: 34514117 DOI: 10.1097/TXD.0000000000001222] [Reference Citation Analysis]
143 Hudson MR, Webb AR, Logan AT, Silverman A, Brueckner AJ. Outcomes of hepatitis C virus nucleic acid testing positive donors in aviremic recipients with delayed direct-acting antiviral initiation. Clin Transplant 2021;:e14386. [PMID: 34132438 DOI: 10.1111/ctr.14386] [Reference Citation Analysis]
144 Raasikh T, Jamali T, Flores A, Cotton RT, Ramanathan V, Tan HP, Hernaez R. Systematic review: hepatitis C viraemic allografts to hepatitis C-negative recipients in solid organ transplantation. Aliment Pharmacol Ther 2021;54:571-82. [PMID: 34265111 DOI: 10.1111/apt.16508] [Reference Citation Analysis]
145 Nam H, Nilles KM, Levitsky J, Ison MG. Donor-derived Viral Infections in Liver Transplantation. Transplantation 2018;102:1824-36. [PMID: 29979345 DOI: 10.1097/TP.0000000000002326] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 3.3] [Reference Citation Analysis]
146 Bowring MG, Shaffer AA, Massie AB, Cameron A, Desai N, Sulkowski M, Garonzik-Wang J, Segev DL. Center-level trends in utilization of HCV-exposed donors for HCV-uninfected kidney and liver transplant recipients in the United States. Am J Transplant 2019;19:2329-41. [PMID: 30861279 DOI: 10.1111/ajt.15355] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
147 Graham JA, Torabi J, Ajaimy M, Akalin E, Liriano LE, Azzi Y, Pynadath C, Greenstein SM, Goldstein DY, Fox AS, Weiss JM, Powell TP, Reinus JF, Kinkhabwala MM, Rocca JP. Transplantation of viral-positive hepatitis C-positive kidneys into uninfected recipients offers an opportunity to increase organ access. Clin Transplant 2020;34:e13833. [PMID: 32072689 DOI: 10.1111/ctr.13833] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
148 Mooney JJ, Purington N, Mohabir P, Dhillon GS. Estimated impact of hepatitis C-positive lung donor utilization on US donor lung supply. Am J Transplant 2020;20:289-97. [PMID: 31394016 DOI: 10.1111/ajt.15558] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
149 O'Connor KJ. An Innovative Approach to Increasing Donor Heart Supply: Will It Work? J Card Fail 2017;23:768-9. [PMID: 28847521 DOI: 10.1016/j.cardfail.2017.08.454] [Reference Citation Analysis]
150 Morales JM, Sawinski D. New insights into the rational use of HCV+ organs worldwide. Clin Transplant 2019;33:e13739. [PMID: 31648391 DOI: 10.1111/ctr.13739] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
151 Kiberd BA, Doucette K, Vinson AJ, Tennankore KK. Hepatitis C virus-infected kidney waitlist patients: Treat now or treat later? Am J Transplant 2018;18:2443-50. [PMID: 29687948 DOI: 10.1111/ajt.14891] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
152 Aslam S, Grossi P, Schlendorf KH, Holm AM, Woolley AE, Blumberg E, Mehra MR; working group members. Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: An ISHLT expert consensus statement. J Heart Lung Transplant 2020;39:418-32. [PMID: 32362393 DOI: 10.1016/j.healun.2020.03.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
153 Axelrod DA, Lentine KL, Balakrishnan R, Chang SH, Alhamad T, Xiao H, Kasiske BL, Bloom RD, Schnitzler MA. Financial Evaluation of Kidney Transplant With Hepatitis C Viremic Donors to Uninfected Recipients. Transplant Direct 2020;6:e627. [PMID: 33204825 DOI: 10.1097/TXD.0000000000001056] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
154 Fabrizi F, Cerutti R, Silva M. HCV-infected solid organ donors, direct-acting antivirals and the current challenges. Expert Rev Clin Pharmacol 2020;13:7-14. [PMID: 31786966 DOI: 10.1080/17512433.2020.1697677] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
155 Kauke M, Haug V, Obed D, Diehm Y, Tchiloemba B, Safi AF, Pomahac B. Donor and Recipient Matching in Facial Vascularized Composite Allotransplantation: A Closer Look at the Donor Pool. Plast Reconstr Surg 2021;148:194-202. [PMID: 34181616 DOI: 10.1097/PRS.0000000000008094] [Reference Citation Analysis]
156 Rawashdeh B, Hulse J, Agarwal A. Transplant of a Kidney from a Hepatitis C Viremic Donor to a Naïve Recipient without Viral Transmission: A Case Report. Am J Case Rep 2021;22:e927532. [PMID: 33953151 DOI: 10.12659/AJCR.927532] [Reference Citation Analysis]
157 Moayedi Y, Fan CPS, Gulamhusein AF, Manlhiot C, Ross HJ, Teuteberg JJ, Khush KK. Current Use of Hearts From Hepatitis C Viremic Donors: A United Network for Organ Sharing Registry Analysis. Circ: Heart Failure 2018;11. [DOI: 10.1161/circheartfailure.118.005276] [Cited by in Crossref: 22] [Cited by in F6Publishing: 2] [Article Influence: 5.5] [Reference Citation Analysis]
158 Luckett K, Kaiser TE, Bari K, Safdar K, Schoech MR, Apewokin S, Diwan TS, Cuffy MC, Anwar N, Shah SA. Use of Hepatitis C Virus Antibody-Positive Donor Livers in Hepatitis C Nonviremic Liver Transplant Recipients. Journal of the American College of Surgeons 2019;228:560-7. [DOI: 10.1016/j.jamcollsurg.2018.12.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
159 Cholankeril G, Li AA, Dennis BB, Toll AE, Kim D, Bonham CA, Nair S, Ahmed A. Increasing Trends in Transplantation of HCV-Positive Livers Into Uninfected Recipients. Clin Gastroenterol Hepatol 2019;17:1634-6. [PMID: 30268562 DOI: 10.1016/j.cgh.2018.09.036] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
160 Gupta G, Kang L, Yu JW, Limkemann AJ, Garcia V, Bandyopadhyay D, Kumar D, Fattah H, Levy M, Cotterell AH, Sharma A, Bhati C, Reichman T, King AL, Sterling R. Long-term outcomes and transmission rates in hepatitis C virus-positive donor to hepatitis C virus-negative kidney transplant recipients: Analysis of United States national data. Clin Transplant 2017;31:e13055. [DOI: 10.1111/ctr.13055] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
161 Smibert OC, Paraskeva MA, Westall G, Snell G. An Update in Antimicrobial Therapies and Infection Prevention in Pediatric Lung Transplant Recipients. Paediatr Drugs 2018;20:539-53. [PMID: 30187362 DOI: 10.1007/s40272-018-0313-1] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
162 Chhatwal J, Samur S, Bethea ED, Ayer T, Kanwal F, Hur C, Roberts MS, Terrault N, Chung RT. Transplanting hepatitis C virus-positive livers into hepatitis C virus-negative patients with preemptive antiviral treatment: A modeling study. Hepatology. 2018;67:2085-2095. [PMID: 29222916 DOI: 10.1002/hep.29723] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 9.5] [Reference Citation Analysis]
163 Sawinski D, Wyatt CM, Locke JE. Expanding the use of hepatitis C-viremic kidney donors. Kidney Int. 2017;92:1031-1033. [PMID: 29055420 DOI: 10.1016/j.kint.2017.09.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
164 Sibulesky L, Limaye AP. NAT testing in recipients of hepatitis C aviremic donor organs. Am J Transplant 2018;18:1030-1030. [DOI: 10.1111/ajt.14568] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
165 Friebus-Kardash J, Gäckler A, Kribben A, Witzke O, Wedemeyer H, Treckmann J, Herzer K, Eisenberger U. Successful early sofosbuvir-based antiviral treatment after transplantation of kidneys from HCV-viremic donors into HCV-negative recipients. Transpl Infect Dis 2019;21:e13146. [PMID: 31306562 DOI: 10.1111/tid.13146] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
166 McLean RC, Reese PP, Acker M, Atluri P, Bermudez C, Goldberg LR, Abt PL, Blumberg EA, Van Deerlin VM, Reddy KR, Bloom RD, Hasz R, Suplee L, Sicilia A, Woodards A, Zahid MN, Bar KJ, Porrett P, Levine MH, Hornsby N, Gentile C, Smith J, Goldberg DS. Transplanting hepatitis C virus-infected hearts into uninfected recipients: A single-arm trial. Am J Transplant 2019;19:2533-42. [PMID: 30768838 DOI: 10.1111/ajt.15311] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 17.0] [Reference Citation Analysis]
167 Huang AC, Mehta N, Dodge JL, Yao FY, Terrault NA. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout. Hepatology 2018;68:449-61. [PMID: 29476694 DOI: 10.1002/hep.29855] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 13.5] [Reference Citation Analysis]
168 Alhamad T, Axelrod D, Lentine KL. The Epidemiology, Outcomes, and Costs of Contemporary Kidney Transplantation. Chronic Kidney Disease, Dialysis, and Transplantation. Elsevier; 2019. pp. 539-554.e5. [DOI: 10.1016/b978-0-323-52978-5.00034-3] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
169 Zhu Y, Shudo Y, Lee R, Woo YJ. Heart Transplant Using Hepatitis C-Seropositive and Viremic Organs in Seronegative Recipients. Ann Transplant 2020;25:e922723. [PMID: 32527989 DOI: 10.12659/AOT.922723] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
170 Lentine KL, Peipert JD, Alhamad T, Caliskan Y, Concepcion BP, Forbes R, Schnitzler M, Chang SH, Cooper M, Bloom RD, Mannon RB, Axelrod DA. Survey of Clinician Opinions on Kidney Transplantation from Hepatitis C Virus Positive Donors: Identifying and Overcoming Barriers. Kidney360 2020;1:1291-9. [PMID: 33251523 DOI: 10.34067/KID.0004592020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 3.5] [Reference Citation Analysis]
171 Colpitts CC, Chung RT, Baumert TF. Entry Inhibitors: A Perspective for Prevention of Hepatitis C Virus Infection in Organ Transplantation. ACS Infect Dis 2017;3:620-3. [PMID: 28812869 DOI: 10.1021/acsinfecdis.7b00091] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
172 Lafargue MC, Caliskan Y, Lentine KL, Riella LV. Opioids and Kidney Transplantation. Semin Nephrol 2021;41:42-53. [PMID: 33896473 DOI: 10.1016/j.semnephrol.2021.02.005] [Reference Citation Analysis]
173 Jandovitz N, Nair V, Grodstein E, Molmenti E, Fahmy A, Abate M, Bhaskaran M, Teperman L. Hepatitis C-positive donor to negative recipient kidney transplantation: A real-world experience. Transpl Infect Dis 2021;23:e13540. [PMID: 33259125 DOI: 10.1111/tid.13540] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
174 Durand CM, Bowring MG, Brown DM, Chattergoon MA, Massaccesi G, Bair N, Wesson R, Reyad A, Naqvi FF, Ostrander D, Sugarman J, Segev DL, Sulkowski M, Desai NM. Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial. Ann Intern Med 2018;168:533-40. [PMID: 29507971 DOI: 10.7326/M17-2871] [Cited by in Crossref: 164] [Cited by in F6Publishing: 61] [Article Influence: 41.0] [Reference Citation Analysis]
175 Cotter TG, Paul S, Sandıkçı B, Couri T, Bodzin AS, Little EC, Sundaram V, Charlton M. Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)‐Viremic Donors Into HCV‐Negative Recipients: Outcomes Following Liver Transplant of HCV‐Viremic Donors. Hepatology 2019. [DOI: 10.1002/hep.30540] [Cited by in Crossref: 22] [Cited by in F6Publishing: 31] [Article Influence: 7.3] [Reference Citation Analysis]
176 Wolfe CR, Ison MG; AST Infectious Diseases Community of Practice. Donor-derived infections: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019;33:e13547. [PMID: 30903670 DOI: 10.1111/ctr.13547] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
177 Bethea ED, Samur S, Kanwal F, Ayer T, Hur C, Roberts MS, Terrault N, Chung RT, Chhatwal J. Cost Effectiveness of Transplanting HCV-Infected Livers Into Uninfected Recipients With Preemptive Antiviral Therapy. Clin Gastroenterol Hepatol. 2019;17:739-747.e8. [PMID: 30138735 DOI: 10.1016/j.cgh.2018.08.042] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
178 Franco A, Balibrea N, Gimeno A, Merino E, Lopez MI, Santiago C, Perez Contreras F. Transplantation of hepatitis C infected kidneys into uninfected recipients. Why not? Nefrologia (Engl Ed) 2018;38:672-3. [PMID: 30006233 DOI: 10.1016/j.nefro.2018.04.005] [Reference Citation Analysis]
179 Madan S, Patel SR, Vlismas P, Hemmige V, Saeed O, Goldstein DJ, Jorde UP. Increasing multiorgan heart transplantation with hepatitis C virus donors in the current-era. J Heart Lung Transplant 2021:S1053-2498(21)02328-7. [PMID: 34176726 DOI: 10.1016/j.healun.2021.05.018] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
180 Kotton CN, van Delden C. Prevention of Bacterial, Viral, Fungal, and Parasitic Infections During the Early Post-transplant Period. In: Manuel O, Ison MG, editors. Infectious Diseases in Solid-Organ Transplant Recipients. Cham: Springer International Publishing; 2019. pp. 39-50. [DOI: 10.1007/978-3-030-15394-6_4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
181 Faust I, Weile J, Fujita B, Kandolf R, Hendig D, Vollmer T, Stan AC, Kellner U, Kuhn J, Gummert JF, Knabbe C. Heart Transplantation in Systemic Sclerosis: New Impulses for Conventional Scleroderma Transplantation Regimen and Scleroderma Diagnostic Monitoring: 2 Case Reports. Transplant Proc 2019;51:865-70. [PMID: 30979477 DOI: 10.1016/j.transproceed.2019.01.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
182 Bova S, Cameron A, Durand C, Katzianer J, LeGrand M, Boyer L, Glorioso J, Toman LP. Access to direct-acting antivirals for hepatitis C-negative transplant recipients receiving organs from hepatitis C-viremic donors. Am J Health Syst Pharm 2021:zxab207. [PMID: 33987658 DOI: 10.1093/ajhp/zxab207] [Reference Citation Analysis]
183 Saberi B, Hamilton JP, Durand CM, Li Z, Philosophe B, Cameron AM, Sulkowski MS, Gurakar A. Utilization of hepatitis C virus RNA-positive donor liver for transplant to hepatitis C virus RNA-negative recipient. Liver Transpl. 2018;24:140-143. [PMID: 28779557 DOI: 10.1002/lt.24838] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
184 Ariyamuthu VK, Tanriover B. Optimizing Utilization of Kidneys from Hepatitis C-Positive Kidney Donors. Clin J Am Soc Nephrol 2021;16:188-90. [PMID: 33451991 DOI: 10.2215/CJN.19431220] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
185 Reyentovich A, Gidea CG, Smith D, Lonze B, Kon Z, Fargnoli A, Pavone J, Rao S, Saraon T, Lewis T, Qian Y, Jacobson I, Moazami N. Outcomes of the Treatment with Glecaprevir/Pibrentasvir following heart transplantation utilizing hepatitis C viremic donors. Clin Transplant 2020;34. [DOI: 10.1111/ctr.13989] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
186 Howard RJ. We listed patients and we should transplant them. Clin Transplant 2020;34:e13882. [PMID: 32294274 DOI: 10.1111/ctr.13882] [Reference Citation Analysis]
187 Nguyen T, Sise ME, Delgado C, Williams W, Reese P, Goldberg D. Race, Education, and Gender Disparities in Transplantation of Kidneys From Hepatitis C Viremic Donors. Transplantation 2021;105:1850-7. [PMID: 33141804 DOI: 10.1097/TP.0000000000003511] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
188 Fabrizi F, Cerutti R, Alfieri CM, Messa P. Updated View on Kidney Transplant from HCV-Infected Donors and DAAs. Pharmaceutics 2021;13:496. [PMID: 33917382 DOI: 10.3390/pharmaceutics13040496] [Reference Citation Analysis]
189 Malinis M, Boucher HW; on behalf of the AST Infectious Diseases Community of Practice. Screening of donor and candidate prior to solid organ transplantation—Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019;33. [DOI: 10.1111/ctr.13548] [Cited by in Crossref: 38] [Cited by in F6Publishing: 24] [Article Influence: 12.7] [Reference Citation Analysis]
190 Abdelbasit A, Hirji A, Halloran K, Weinkauf J, Kapasi A, Lien D, Nagendran J, Doucette K. Lung Transplantation from Hepatitis C Viremic Donors to Uninfected Recipients. Am J Respir Crit Care Med 2018;197:1492-6. [DOI: 10.1164/rccm.201712-2614le] [Cited by in Crossref: 24] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
191 Smith DE, Chen S, Fargnoli A, Lewis T, Galloway AC, Kon ZN, Moazami N. Impact of Early Initiation of Direct-Acting Antiviral Therapy in Thoracic Organ Transplantation From Hepatitis C Virus Positive Donors. Semin Thorac Cardiovasc Surg 2021;33:407-15. [PMID: 32621962 DOI: 10.1053/j.semtcvs.2020.06.045] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
192 Mikulic D, Mrzljak A. Liver transplantation and aging. World J Transplant 2020; 10(9): 256-266 [PMID: 32995320 DOI: 10.5500/wjt.v10.i9.256] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]